Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. FDX
5. IBM
6. META
7. MU
8. ACN
9. USO
10. NVDA

Go back to Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)
(NASDAQ: KITE) Delayed: 179.79 --0 (-0%)
Previous Close $179.79    52 Week High $89.84 
Open $17.44    52 Week Low $38.41 
Day High $179.79    P/E N/A 
Day Low $179.79    EPS $0.00 
Volume 146,685